These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 19733905)

  • 1. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy.
    Senti G; Graf N; Haug S; Rüedi N; von Moos S; Sonderegger T; Johansen P; Kündig TM
    J Allergy Clin Immunol; 2009 Nov; 124(5):997-1002. PubMed ID: 19733905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study.
    Senti G; von Moos S; Tay F; Graf N; Sonderegger T; Johansen P; Kündig TM
    J Allergy Clin Immunol; 2012 Jan; 129(1):128-35. PubMed ID: 21996342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intradermal grass pollen immunotherapy increases T
    Slovick A; Douiri A; Muir R; Guerra A; Tsioulos K; Hay E; Lam EPS; Kelly J; Peacock JL; Ying S; Shamji MH; Cousins DJ; Durham SR; Till SJ
    J Allergy Clin Immunol; 2017 Jun; 139(6):1830-1839.e13. PubMed ID: 27773851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy.
    Rondón C; Blanca-López N; Campo P; Mayorga C; Jurado-Escobar R; Torres MJ; Canto G; Blanca M
    Allergy; 2018 Apr; 73(4):905-915. PubMed ID: 29168570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
    Hylander T; Latif L; Petersson-Westin U; Cardell LO
    J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
    Roberts G; Hurley C; Turcanu V; Lack G
    J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of microneedles and adhesive-tape stripping in skin preparation for epicutaneous allergen delivery.
    Spina L; Weisskopf M; von Moos S; Graf N; Kündig TM; Senti G
    Int Arch Allergy Immunol; 2015; 167(2):103-9. PubMed ID: 26279062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
    Klimek L; Schendzielorz P; Pinol R; Pfaar O
    Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
    Rossi RE; Monasterolo G
    Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.
    Scadding GW; Calderon MA; Shamji MH; Eifan AO; Penagos M; Dumitru F; Sever ML; Bahnson HT; Lawson K; Harris KM; Plough AG; Panza JL; Qin T; Lim N; Tchao NK; Togias A; Durham SR;
    JAMA; 2017 Feb; 317(6):615-625. PubMed ID: 28196255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timothy grass pollen therapeutic vaccine: optimal dose for subcutaneous immunotherapy.
    Sola J; da Silva Ferreira JA; Dionicio Elera J; Plácido JL; Pereira C; Fonseca J; Panizo C; Inácio LF; Cancelleire N; Zubeldia Ortuño JM; Landeta A; Madariaga B; Martínez A
    Immunotherapy; 2016; 8(3):251-63. PubMed ID: 26760111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial.
    Senti G; Prinz Vavricka BM; Erdmann I; Diaz MI; Markus R; McCormack SJ; Simard JJ; Wüthrich B; Crameri R; Graf N; Johansen P; Kündig TM
    Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17908-12. PubMed ID: 19001265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
    Rossi RE; Monasterolo G; Coco G; Operti D
    Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials.
    Senti G; von Moos S; Tay F; Graf N; Johansen P; Kündig TM
    Allergy; 2015 Jun; 70(6):707-10. PubMed ID: 25704072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both sublingual and supralingual routes of administration are effective in long-term allergen-specific immunotherapy.
    Panzner P; Petráš M; Sýkora T; Lesná IK; Liška M
    Allergy Asthma Proc; 2011; 32(2):142-50. PubMed ID: 21439167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of treatment.
    Subiza J; Feliú A; Subiza JL; Uhlig J; Fernández-Caldas E
    Clin Exp Allergy; 2008 Jun; 38(6):987-94. PubMed ID: 18445082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.